Immunogenicity of Outer Membrane Proteins VirB9-1 and VirB9-2, a Novel Nanovaccine against Anaplasma marginale

Zhao, Liang, Mahony, Donna, Cavallaro, Antonino S., Zhang, Bing, Zhang, Jun, Deringer, James R., Brown, Wendy C., Zhao, Chun-Xia, Yu, Chengzhong, Mitter, Neena and Middelberg, Anton P. J. (2016) Immunogenicity of Outer Membrane Proteins VirB9-1 and VirB9-2, a Novel Nanovaccine against Anaplasma marginale. PLoS One, 11 4: . doi:10.1371/journal.pone.0154295


Author Zhao, Liang
Mahony, Donna
Cavallaro, Antonino S.
Zhang, Bing
Zhang, Jun
Deringer, James R.
Brown, Wendy C.
Zhao, Chun-Xia
Yu, Chengzhong
Mitter, Neena
Middelberg, Anton P. J.
Title Immunogenicity of Outer Membrane Proteins VirB9-1 and VirB9-2, a Novel Nanovaccine against Anaplasma marginale
Formatted title
Immunogenicity of Outer Membrane Proteins VirB9-1 and VirB9-2, a Novel Nanovaccine against Anaplasma marginale
Journal name PLoS One   Check publisher's open access policy
ISSN 1932-6203
Publication date 2016-04-26
Sub-type Article (original research)
DOI 10.1371/journal.pone.0154295
Open Access Status DOI
Volume 11
Issue 4
Total pages 20
Place of publication San Francisco, United States
Publisher Public Library of Science
Collection year 2017
Language eng
Formatted abstract
Anaplasma marginale is the most prevalent tick-borne livestock pathogen and poses a significant threat to cattle industry. In contrast to currently available live blood-derived vaccines against A. marginale, alternative safer and better-defined subunit vaccines will be of great significance. Two proteins (VirB9-1 and VirB9-2) from the Type IV secretion system of A. marginale have been shown to induce humoral and cellular immunity. In this study, Escherichia coli were used to express VirB9-1 and VirB9-2 proteins. Silica vesicles having a thin wall of 6 nm and pore size of 5.8 nm were used as the carrier and adjuvant to deliver these two antigens both as individual or mixed nano-formulations. High loading capacity was achieved for both proteins, and the mouse immunisation trial with individual as well as mixed nano-formulations showed high levels of antibody titres over 107 and strong T-cell responses. The mixed nano-formulation also stimulated high-level recall responses in bovine T-cell proliferation assays. These results open a promising path towards the development of efficient A. marginale vaccines and provide better understanding on the role of silica vesicles to deliver multivalent vaccines as mixed nano-formulations able to activate both B-cell and T-cell immunity, for improved animal health.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 2 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Mon, 09 May 2016, 10:36:53 EST by Dr Neena Mitter on behalf of Centre for Plant Science